Stopping Mounjaro or Wegovy: What the BMJ Paper Really Shows

The finding that matters

Stopping Mounjaro or Wegovy is often followed by weight regain, and a new BMJ systematic review gives the clearest warning yet: weight-loss medication should not be started without a plan for what happens afterwards. Across 37 studies involving 9,341 adults, weight increased after medication cessation by an average of 0.4 kg per month, with cardiometabolic markers projected to drift back towards baseline within 1.4 years. [1]

This matters most for adults using these medicines for obesity, overweight with metabolic risk, or weight-related health problems. The central lesson is straightforward: the injection can reduce appetite, but it cannot by itself build the system required to maintain the result. That system has to be designed.

The BMJ paper in plain English

The BMJ paper was a systematic review and meta-analysis of weight regain after stopping weight management medication. It included randomised trials, non-randomised trials and observational studies where adults with overweight or obesity used weight management medication for at least eight weeks and were followed for at least four weeks after stopping. [1]

The review found that weight regain after stopping medication was faster than after behavioural weight management programmes, independent of the initial weight loss achieved. [1] That finding is clinically important because it shows how fragile medication-induced weight loss can be once the pharmacological support is withdrawn.

It does not show that GLP-1 drugs are ineffective. These medicines can produce substantial weight loss and meaningful improvements in metabolic risk markers. The issue is durability. A treatment can work well during active use and still require a careful maintenance plan when the dose is reduced, paused or stopped.

Why regain happens after stopping

Weight regain is often discussed as though it were a lapse in discipline. That framing is medically thin. When weight is lost, the body does not passively accept the new lower weight. Appetite can rise. Energy expenditure may fall. Food reward can increase.

GLP-1 and GIP/GLP-1 drugs such as semaglutide and tirzepatide reduce appetite and food intake. They can quieten "food noise", improve satiety and help patients sustain a lower energy intake. When the drug is reduced or stopped, the pharmacological appetite control is weakened or removed. If nothing durable has been built underneath it, appetite commonly returns into the same environment that existed before treatment.

That is the predictable clinical sequence: appetite suppression during treatment → weight loss during treatment → appetite return after dose reduction or cessation → weight regain if the maintenance system is inadequate. The useful question is not whether the patient has enough willpower. The useful question is whether the treatment created enough physiological and behavioural stability to survive a lower dose.

What the trial evidence shows

The SURMOUNT-4 trial is a clear example. Adults with obesity received tirzepatide for 36 weeks and lost an average of 20.9% body weight. Those who continued tirzepatide maintained and augmented results. Those switched to placebo regained substantial weight. [2]

The STEP 1 extension showed a similar pattern after semaglutide withdrawal. One year after stopping semaglutide 2.4 mg, participants regained around two-thirds of their prior weight loss, and cardiometabolic improvements moved back towards baseline. [3]

These findings should not surprise us. Obesity behaves like a chronic, relapsing metabolic condition for many patients. That does not mean every patient must remain on medication indefinitely. It does mean the decision to continue, reduce, pause or stop should be made deliberately, with monitoring.

The missing clinical question

Most public discussion about GLP-1 medication is trapped in a crude argument about whether the drugs are good or bad. The more important question is: what needs to be true for the benefits to persist when the dose is reduced, stopped, or continued long term?

A patient may lose substantial weight on semaglutide or tirzepatide. Their HbA1c may improve. Blood pressure may fall. But these improvements do not prove that the underlying system has changed enough to survive withdrawal. The drug has altered appetite physiology. It has not automatically:

• preserved lean mass or built strength
• improved sleep architecture
• reviewed weight-promoting medication
• corrected protein insufficiency
• changed the home food environment
• created relapse thresholds or a written maintenance plan

A serious GLP-1 pathway should treat the period after dose reduction as a clinical phase in its own right.

Body composition: the hidden issue

Most patients are taught to focus on weight. The scale matters, but it is incomplete. The quality of weight loss matters too.

A person may lose 20 kg and still finish treatment with too little muscle, poor strength, low protein intake, reduced training capacity, persistent sleep disruption, and an appetite pattern that becomes unstable as soon as the drug is reduced.

Lean mass is not decorative. It contributes to function, glucose disposal, resting energy expenditure, training capacity, fall-risk reduction, and long-term resilience. The STEP 1 body composition substudy suggested semaglutide produced greater reductions in fat mass than lean body mass [6], but other analyses indicate lean mass can still account for a meaningful proportion of total weight lost during GLP-1 treatment, making resistance training and nutrition important during and after treatment. [7]

This is why a GLP-1 exit strategy should not rely on weight alone. The aim is not simply to weigh less. The aim is to become metabolically harder to destabilise.

What a GLP-1 exit strategy should include

A GLP-1 exit strategy should begin before the final prescription is written. It should answer five questions.

1. What changed during treatment?

Weight is only one marker. A proper review should include weight trend, waist circumference, blood pressure, HbA1c or fasting glucose, lipid profile, liver markers, renal function, medication list, side effects, appetite pattern, training capacity and body composition where available.

2. What was lost?

A reduction in scale weight may hide inadequate protein intake, loss of lean tissue, falling strength, reduced energy or poor training tolerance. The clinician should know what question is being answered.

3. What is likely to return as the dose falls?

Patients should be warned about predictable physiology: hunger returning earlier in the day, evening cravings, larger portions, alcohol increasing appetite, weight rising before the patient feels out of control. These should not be treated as surprises. They are exactly what an exit plan should anticipate.

4. What replaces the appetite control?

As the medication is reduced, other structures need to carry more of the load: protein at the first meal, fibre with main meals, resistance training two to three times weekly, walking after meals, alcohol rules, sleep protection, fewer high-risk foods at home, planned meals during the highest-risk part of the day. This is not lifestyle decoration. It is replacement architecture.

5. What data will trigger a change in plan?

Useful triggers might include: weight rising for four consecutive weeks, waist increasing by more than a defined amount, blood pressure rising after prior improvement, HbA1c worsening, hunger becoming intrusive, binge episodes returning. The principle is simple: decide early what will count as drift.

A practical timeline

This is a clinical framework to discuss with your own clinician. It is not personal medical advice.

When to involve your clinician

You should involve your clinician before stopping or tapering GLP-1 medication if: you have type 2 diabetes; you take insulin, sulfonylureas or other glucose-lowering medication; you have a history of pancreatitis; you have gallstones or gallbladder symptoms; you have severe reflux, vomiting, constipation or dehydration; you have kidney disease; you are pregnant, trying to conceive or breastfeeding; you have an eating-disorder history; your blood pressure medication may now be too strong after weight loss.

Weight loss can alter the need for blood pressure medication, diabetes medication, reflux medication and other drugs. That does not justify casual stopping — it justifies proper deprescribing review. If you want your full medication list reviewed in context, an Independent Medication Review produces a written clinical assessment of everything you are taking.

When to seek urgent help

Seek urgent medical help if you develop: severe persistent abdominal pain especially if it radiates to the back; repeated vomiting; inability to keep fluids down; marked dizziness, confusion or collapse; symptoms of severe allergic reaction; symptoms of hypoglycaemia (sweating, shaking, confusion, palpitations, drowsiness or collapse); chest pain or acute neurological symptoms.

In January 2026, the MHRA strengthened warnings on acute pancreatitis for GLP-1 and dual GLP-1/GIP receptor agonists, advising urgent medical attention for severe persistent abdominal pain that may radiate to the back and may be accompanied by nausea and vomiting. [9]

Final thought

The BMJ paper should change the way these drugs are discussed. It shows that medication-induced weight loss is powerful and biologically fragile. The weight may come off during treatment, but the conditions required to maintain that loss are not automatically created by the prescription.

The central question after GLP-1 treatment is simple: has the patient become physiologically stable enough to maintain the result when pharmacological appetite control is reduced?

That is the real exit strategy.